Ataxia telangiectasia - Pipeline Insight, 2021

Publisher Name :
Date: 15-Mar-2021
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Ataxia telangiectasia - Pipeline Insight, 2021," report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Ataxia telangiectasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Ataxia telangiectasia Understanding

Ataxia telangiectasia: Overview

Ataxia-telangiectasia is a rare inherited disorder that affects the nervous system, immune system, and other body systems. The disease is characterized by progressive difficulty with coordinating movements (ataxia) beginning in early childhood. Affected children typically develop difficulty in walking, problems with balance and hand coordination, involuntary jerking movements (chorea), muscle twitches (myoclonus), and disturbances in nerve function (neuropathy). Ataxia-telangiectasia is inherited in an autosomal recessive pattern. A diagnosis of ataxia telangiectasia is made based upon a detailed patient history, a thorough clinical evaluation, identification of characteristic symptoms, and a variety of specialized tests including blood tests, magnetic resonance imaging (MRI), and karyotyping. Treatment for AT is directed toward control of symptoms. For respiratory infections, therapy with an antibiotic drug, postural drainage (with the head lower than the rest of the body) of the bronchial tubes and lungs, and gammaglobulin injections in some cases may be effective.

"Ataxia telangiectasia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ataxia telangiectasia pipeline landscape is provided which includes the disease overview and Ataxia telangiectasia treatment guidelines. The assessment part of the report embraces, in depth Ataxia telangiectasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ataxia telangiectasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Ataxia telangiectasia R&D. The therapies under development are focused on novel approaches to treat/improve Ataxia telangiectasia.

Ataxia telangiectasia Emerging Drugs Chapters

This segment of the Ataxia telangiectasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ataxia telangiectasia Emerging Drugs

- IB1001: IntraBio

IB1001 (N-Acetyl-L-Leucine) is an orally administered small molecule, calcium channel modulator and modified amino acid. IntraBio is developing IB1001 for other neurodegenerative diseases and lysosomal storage disorders. The drug is in Phase II clinical studies for the treatment of Ataxia Telangiectasia.

- Ery-Dex: EryDel

Ery-Dex is a novel, proprietary method of encapsulating a potent steroid, dexamethasone sodium phosphate, in red blood cells allowing for its gradual dephosphorylation and release of dexamethasone in a patient's circulation for up to 30 days, providing the potential for effective treatment and preventing the unacceptable systemic side effects of oral or intravenous steroid treatment. The drug is in Phase 3 clinical study for the treatment of Ataxia Telangiectasia patients.

Further product details are provided in the report……..

Ataxia telangiectasia: Therapeutic Assessment

This segment of the report provides insights about the different Ataxia telangiectasia drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Ataxia telangiectasia

There are approx. 6+ key companies which are developing the therapies for Ataxia telangiectasia. The companies which have their Ataxia telangiectasia drug candidates in the most advanced stage, i.e. Phase III include, Orasis Pharmaceuticals.

- Phases

DelveInsight's report covers around 6+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Ataxia telangiectasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

- Parenteral

- Intravitreal

- Subretinal

- Topical

- Molecule Type

Products have been categorized under various Molecule types such as

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Gene therapy

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ataxia telangiectasia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ataxia telangiectasia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ataxia telangiectasia drugs.

Ataxia telangiectasia Report Insights

- Ataxia telangiectasia Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Ataxia telangiectasia Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Ataxia telangiectasia drugs?

- How many Ataxia telangiectasia drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ataxia telangiectasia?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ataxia telangiectasia therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Ataxia telangiectasia and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- IntraBio

- EryDel

- ChromaDex

- Grace Therapeutics

Key Products

- IB1001

- Ery-Dex

- Nicotinamide riboside

- Betamethasone oral spray

Ataxia telangiectasia - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
Ataxia telangiectasia: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
Pipeline Therapeutics
* Comparative Analysis
Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
Ataxia telangiectasia - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
* Ataxia telangiectasia companies' collaborations, Licensing, Acquisition -Deal Value Trends
Ataxia telangiectasia Collaboration Deals
* Company-Company Collaborations (Licensing / Partnering) Analysis
* Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
* Comparative Analysis
Ery-Dex: EryDel
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
* Comparative Analysis
IB1001: IntraBio
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
* Comparative Analysis
Drug name: Company name
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
* Comparative Analysis
Nicotinamide riboside: ChromaDex
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
* Comparative Analysis
Ataxia telangiectasia Key Companies
Ataxia telangiectasia Key Products
Ataxia telangiectasia- Unmet Needs
Ataxia telangiectasia- Market Drivers and Barriers
Ataxia telangiectasia- Future Perspectives and Conclusion
Ataxia telangiectasia Analyst Views
Ataxia telangiectasia Key Companies
Appendix

List of Tables

Table 1 Total Products for Ataxia telangiectasia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Ataxia telangiectasia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Histone Deacetylase (HDAC) Inhibitors Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 87
    The global Histone Deacetylase (HDAC) Inhibitors market was valued at US$ 615.2 million in 2023 and is anticipated to reach US$ 1223.2 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030. North American market for Histone Deacetylase (HDAC) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Histone Deacetylase (HDAC) Inhibitor......
  • Global Esomeprazole Magnesium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 74
    The global Esomeprazole Magnesium market was valued at US$ 5287 million in 2023 and is anticipated to reach US$ 9451.5 million by 2030, witnessing a CAGR of 8.3% during The forecast period 2024-2030. North American market for Esomeprazole Magnesium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Esomeprazole Magnesium is estimated to increase from $ million in 2......
  • Global Combination Therapy Drug Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Combination Therapy Drug market was valued at US$ 105 million in 2023 and is anticipated to reach US$ 166.7 million by 2030, witnessing a CAGR of 4.1% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is......
  • Global Axitinib Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 68
    The global Axitinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The......
  • Global Lyme Disease Vaccine Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 70
    The lyme disease vaccine can reduce lyme disease incidence, reduce symptoms and reduce mortality. Lyme disease is a tick-borne infection of spirochete, a natural disease caused by borrelia burgdorferi. The global Lyme Disease Vaccine market was valued at US$ 257 million in 2023 and is anticipated to reach US$ 763 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at......
  • Global Transdermal Absorption Patch Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Transdermal Absorption Patch market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Transdermal Absorption Patch is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Transdermal Absorption Patch is estimated to increase from $ million i......
  • Global Ketoprofen Patches Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    Ketoprofen patch, indications for The treatment of symptoms caused by The following diseases: rheumatoid arthritis and rheumatoid arthritis The global Ketoprofen Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Ketoprofen Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast per......
  • Global Methyl Salicylate Patches Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 82
    The global Methyl Salicylate Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to......
  • Global Diclofenac Patches Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Diclofenac Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs